Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition
Susheel Kumar Nethi
(Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, USA; Nanovaccine Institute, Iowa State University, Ames, IA, USA)
Venugopal Gunda
(Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA)
Nagabhishek Sirpu Natesh
(Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA; Roy Blunt Nextgen Precision Health, University of Missouri, Columbia, MO, USA)
Brianna M. White
(Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, USA)
Adam S. Mullis
(Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, USA)
Balaji Narasimhan
(Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, USA; Nanovaccine Institute, Iowa State University, Ames, IA, USA)
Surinder K. Batra
(Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA)
Surya K. Mallapragada
(Department of Chemical and Biological Engineering, Iowa State University, Ames, IA, USA; Nanovaccine Institute, Iowa State University, Ames, IA, USA; Corresponding author)
Satyanarayana Rachagani
(Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA; Roy Blunt Nextgen Precision Health, University of Missouri, Columbia, MO, USA; Corresponding author)
Journal: iScience
•
• Elsevier
• ISSN: 2589-0042
Abstract
Summary: Pancreatic cancer (PC) exhibits profound metabolic adaptations that support tumor progression, survival, and therapy resistance. Hypoxia-inducible factor-1α (HIF-1α) is a key regulator of these processes, promoting metabolic reprogramming and chemoresistance. Given that mitochondrial metabolites modulate HIF-1α stability, targeting mitochondrial metabolism offers a promising therapeutic strategy. Niclosamide (Nic), a clinically approved anthelmintic, disrupts mitochondrial function but is limited by poor bioavailability. To overcome this, we developed polyanhydride-based Nic nanoparticles (NicNps) to enhance bioavailability and efficacy. NicNps impaired mitochondrial function, suppressed metabolism, downregulated HIF-1α, and inhibited growth of PC cells and orthotopic gemcitabine (Gem)-resistant mouse tumor models. Notably, NicNps combined with Gem overcame therapy resistance by synergistically reducing tumor hypoxia and HIF-1α-driven metabolic reprogramming. These findings highlight NicNps as a mitochondria-targeted, nanoparticle-based therapy that enhances Nic’s bioavailability while suppressing HIF-1α-driven adaptations. NicNps in combination with Gem offer a promising strategy to overcome therapy resistance and improve treatment outcomes in patients with pancreatic cancer.